NAM Healthy Longevity QuickFire Challenge

Awardees

波士顿儿童医院 波士顿儿童医院的团队旨在识别可行的目标，以通过与长期存在的人类在特殊的长寿物种中交叉的基因组特征来延长长寿。

Byteflies Byteflies is creating a hematology-oncology-specific digital health solution with the potential to objectively track disease progression and detect treatment adverse effects such as neurotoxicity and inflammation at an early stage.

Hamamatsu University School of Medicine Hamamatsu大学医学院队的旨在为阿尔茨海默病患者发育一种新的脑衍生的肽，为阿尔茨海默病进行创新的透皮治疗。

SYNCSENSE 通过专有的智能AI驱动的传感器和VR平台，SyncSense旨在将运动设备变换为接触和适应性的外交经验，可防止和治疗与身体不活动和衰老有关的疾病。

Overview

Today, 8.5% of people worldwide are aged 65 and over. By 2050, this percentage is projected to more than double, reaching 1.6 billion.[1]

由于医学，公共卫生和社会和经济发展中的戏剧性突破，在过去的世纪，世界许多地区的人类寿命大幅增加。

However, a rapidly aging world population does pose challenges as well as opportunities - to economies, health systems, and social structures worldwide in addition to the physical, mental, and social well-being of the individual.

随着我们达到前所未有的寿命，我们觉得我们必须关注帮助增加人类健康血管，并在早期预防，拦截和治愈疾病时更好地提高婴儿期。

一个好主意可以来自任何地方。这就是我们的原因合作with the National Academy of Medicine, which aims to grow emerging ideas in research and innovation with the健康长寿全球竞争。通过这些举措，我们的目标to identify and catalyze new cross-disciplinary ideas and innovation that we believe could ultimately lead to novel solutions for aging free from debilitating disease.

约翰逊和约翰逊创新很自豪能够推出NAM健康长寿Quickfire挑战，一个exclusive series of opportunities for international Catalyst Award winners to apply for additional grant funding and support from Johnson & Johnson Innovation as they continue on their innovation journey.

Beginning on June 8, 2021, 2020 international Catalyst Award winners can submit applications for consideration of up to $750,000 in grant funding and mentorship opportunities from experts at the Johnson & Johnson Family of Companies.*

*限制适用。

[1]The National Academy of Medicine, data on file.

Areas of Focus

潜在的解决方案必须包括旨在在以下一个或多个领域中转化患者结果的创新：

• Oncology, including:
  • 癌症预防
    • 使用非侵入性技术鉴定出现最高风险的个体患病风险
      • 分子生物标志物
      • 临床/表型生物标志物
      • 数据/示例访问和AI驱动平台
    • 逆转组织特异性表观遗传变化与加速衰老和血管生成相关的新型方式
    • Novel modalities targeting mechanisms of DNA damage and mutagenesis such as:
      • Chronic inflammation/ROS
      • 致癌微生物组
  • Cancer Interception
    • Novel modalities targeting initiating genomic/epigenomic driver events in solid and hematologic malignancies
    • 本地化的器官特异性药物交付的新颖平台，以避免或降低全身毒性
    • Novel modalities influencing immune response to pre-malignant disease

• 神经科学, including:
  • Neurodegeneration or Neuropsychiatry
    • Novel disease modifying mechanisms of actions with a strong human genetic link/predicted translation to human disease, such as neuroinflammation or autophagy
    • Novel modalities targeting the brain with minimal systemic exposure/effect
    • 经过验证的新技术，包括数字生物标志物，可以
      • 预测神经变性疾病的早期发病阶段
      • 快速识别受试者更容易成为耐药，复发或/和开发自杀思想
      • 将数字治疗性部署为独立或与我们的一家管道产品组合
    • 进入良好的小型数据集的良好特征的群组梳理临床表型和基因分型
    • 预防细胞老化（例如，降低氧化应激，自由基损伤，慢性炎症）
  • 基于器官系统的方法和技术，可能降低衰老功能下降风险，包括：
    • Cognitive and brain aging
    • Functional mobility and chronic pain
• Data Sciences, including具有深层分子数据的健康老龄化群体及纵向跟踪表型
• 骨科， 包括预防和治疗骨关节炎
• Consumer Health，包括潜在的解决方案：
  • 女性40岁以上，特别是在更年期，偏头痛，心理健康和新陈代谢的领域
  • Chronic pain
  • 皮肤屏障强化，恢复皮肤健康功能，以及敏感皮肤的保护
  • 用于跟踪/参与老化群体的应用程序，与其他数据源/类型（如语音，视频，EMR等）而不是个人报告的结果

Evaluation Criteria

Potential solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

• Uniqueness of the idea
• 潜在影响
• 理念的可行性和概括性
• Thoroughness of approach
• 确定关键资源并计划进一步的想法
• Progress and milestones achieved since receiving previous Catalyst and/or QuickFire Challenge awards

关于约翰逊和约翰逊的创新

ld乐动强生公司创新有限责任公司在工作pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us atwww.jnjinnovation.com。